Est. 2026 — GLP-1 & Metabolic Data Layer
Glucax builds the data and analytics layer for companies operating at the frontier of metabolic health — from continuous glucose monitoring pipelines to GLP-1 treatment tracking and insulin sensitivity modeling.
Gluco (γλυκύς) — Greek for sweet. The molecule at the center of the metabolic health revolution.// Core infrastructure
Structured ingestion and normalization of continuous glucose monitor data from Dexcom, Abbott, and next-generation devices — longitudinal, interoperable, and ready for clinical analysis.
Track metabolic response to GLP-1 agonists at the patient and cohort level. Glucax provides the analytics layer for clinics, telehealth platforms, and pharmaceutical outcomes research.
HbA1c, fasting insulin, HOMA-IR, visceral fat estimation, and inflammatory markers — unified under a single API designed for metabolic health platforms and clinical decision support tools.
// Why now
GLP-1 drugs have created a $50 billion market overnight. The data infrastructure to support it doesn't exist yet.
Ozempic and Wegovy have moved metabolic health from a chronic disease management problem to a mainstream consumer and clinical priority. Hundreds of new companies — GLP-1 clinics, telehealth platforms, CGM analytics startups, metabolic health apps — are building in this space right now.
Every one of them needs the same foundational infrastructure: glucose data pipelines that handle real-world messiness, treatment response analytics that go beyond weight loss to actual metabolic markers, and biomarker APIs that speak the clinical language of endocrinology.
Glucax is that infrastructure layer. Built for the speed of the GLP-1 market, with the precision that metabolic medicine demands.
// Get in touch
We are selectively onboarding infrastructure partners and early customers. Tell us about your platform and what you are building in metabolic health.